Rimegepant: Effective Migraine Relief for Triptan-Sensitive Adults

Research Summary

In a study published in the journal Cephalalgia, researchers explored the efficacy of rimegepant, a calcitonin gene-related peptide antagonist, for migraine treatment in adults unsuitable for triptans. This phase 4 trial involved 585 participants who either could not tolerate triptans, found them ineffective, or had contraindications. Participants were randomly assigned rimegepant or a placebo to treat a migraine attack. Results showed that 55.9% of those taking rimegepant experienced pain relief within two hours, compared to 32.7% with placebo, achieving all key secondary endpoints. No severe adverse effects were reported, highlighting rimegepant as an effective and well-tolerated alternative.

Study Details

📄 Title: Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trial.

👥 Research Team: Ashina M et al.

📚 Published In: Cephalalgia

📅 Publication Date: 2025 Nov

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.